Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath by breath: new study maps lung drug delivery in asthma and COPD

NCT ID NCT05445349

Knowledge-focused Sponsor: Medisol Development Kft. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured breathing patterns in 163 adults with asthma or COPD to help computers predict how much of an inhaled drug actually reaches the lungs. Researchers used these real-world breathing measurements to improve simulations of aerosol drug deposition. The goal is to make inhaled treatments more personalized and effective for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

163 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We are recruiting participants for our test from different levels of healthcare servicing (university centre, regional institute, county hospital, panel clinic) aiming to minimize centre specific effects.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosed obstructive lung disease (asthma or COPD) * proper usage of inhalation tool after being educated * availability of whole body plethysmography measurement data from the last 6 months or the possibility to perform them before the start of the study * subject under outpatient/inpatient therapy * capable of acting and cooperating Exclusion Criteria: * the patient doesn't align with any of the criteria mentioned above * the patient is incapable of filling out the questionnaire/questionnaires' parts that are accorded to him/her * the patient doesn't agree to have data collected of him/her * diagnosed heavy, not treated chronic illness * not properly carried out /not evaluable lung function (spirometry) examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma COPD

Contacts and locations

Locations

  • Pest County Pulmonology Hospital

    Törökbálint, 2045, Hungary

  • St. Borbala Hospital

    Tatabánya, Hungary

  • University of Debrecen

    Debrecen, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.